Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by Novartis" The following 135 pages are in this category, out of 135 total. This list may not reflect recent changes. A.
E. W. Kemble's "Death's Laboratory" on the cover of Collier's (June 3, 1905). A patent medicine, also known as a proprietary medicine or a nostrum (from the Latin nostrum remedium, or "our remedy") is a commercial product advertised to consumers as an over-the-counter medicine, generally for a variety of ailments, without regard to its actual effectiveness or the potential for harmful side ...
Pliny the Elder, who lived from 23–79 CE, first gave a name to what we now call pills, calling them pilula. [2] Pliny also wrote Naturalis Historia a collection of 38 books and the first pharmacopoea. Pedanius Dioscorides wrote De Materia Medica (c. 40 – 90 CE); this book dominated the area of drug knowledge for some 1500 years until the ...
In 2013, the Indian Supreme Court issued a decision rejecting Novartis' patent application in India on the final form of Gleevec, Novartis's cancer drug; the case caused great controversy. [45] In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards ...
Plavix. This anti-clot or blood thinner most prescribed to prevent heart attack or stroke claims the title of second-best selling drug in the world, with $9.4 billion in global sales in 2010.
With another earnings season upon us, The Fool's health care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on ...
In 2013, the Supreme Court of India upheld the rejection of the patent application of Glivec by Novartis, [31] ending the 10-years battle between the proprietary drug tycoon and the local patent law. Since 1993, Novartis has started to register patent for Glivec and its active ingredients worldwide without defeats. [31]
Swiss drug company Novartis AG (NVS) dove into the recent wave of pharma dealmaking today. The industry has been in consolidation mode as many drugs are due to come off patent in recent years, as ...